Chemical inhibitors of TFIIIC90 are integral in regulating its function within the transcriptional machinery. Triptolide serves as one such inhibitor, directly impeding the assembly of the transcription factor III C (TFIIIC) complex, thereby inhibiting the activity of TFIIIC90. Another chemical, DrB (Dichlorobenzimidazole Riboside), targets RNA polymerase III activity, which is contingent on TFIIIC90 for the initiation of transcription at specific genes. This inhibition is critical as it prevents TFIIIC90 from fulfilling its role in the transcription initiation process. BMH-21 is known to bind to RNA polymerase I, leading to the enzyme's degradation. This action indirectly inhibits TFIIIC90 activity by reducing the overall pool of transcriptional resources, thus limiting RNA polymerase III interactions with TFIIIC90.
The chemical CX-5461 specifically inhibits RNA polymerase I transcription, which can limit the availability of transcription machinery for TFIIIC90's role in RNA polymerase III transcription. ML-60218 blocks the initiation step of RNA polymerase III transcription, where TFIIIC90 is essential for proper gene expression control. Further, H3B-8800 and Pladienolide B inhibit spliceosome-mediated splicing, which can indirectly limit the number of RNA targets that require TFIIIC90 for their transcription by RNA polymerase III. Similarly, spliceostatin A and Isoginkgetin target the spliceosome, thereby reducing the processing of RNA targets for TFIIIC90 and inhibiting its role in RNA polymerase III transcription. Meayamycin, another splicing inhibitor, affects the maturation of RNA transcripts that TFIIIC90 acts upon, thus indirectly inhibiting its function. Lastly, Madrasin disrupts splicing fidelity, which may decrease the pool of RNA transcripts necessitating TFIIIC90 for their transcription, further inhibiting the protein's activity within the cell. Each of these chemicals intervenes in cellular pathways and processes to inhibit the function of TFIIIC90, thereby regulating transcriptional activities where TFIIIC90 is normally a key component.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide inhibits the transcription factor III C (TFIIIC) complex assembly, indirectly inhibiting TFIIIC90 activity. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DrB inhibits RNA polymerase III activity, which relies on TFIIIC90 for initiating transcription at certain genes. | ||||||
BMH-21 | 896705-16-1 | sc-507460 | 10 mg | $165.00 | ||
BMH-21 binds to RNA polymerase I, leading to degradation of the enzyme, indirectly inhibiting TFIIIC90 by limiting transcriptional resources. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
CX-5461 selectively inhibits RNA Polymerase I transcription, which can indirectly limit the availability of TFIIIC90 for RNA Polymerase III transcription. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B inhibits the spliceosome, potentially decreasing the RNA Pol III transcriptional targets where TFIIIC90 is involved. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Spliceostatin A targets the spliceosome, indirectly inhibiting TFIIIC90 by potentially reducing the RNA Pol III transcription workload. | ||||||
Isoginkgetin | 548-19-6 | sc-507430 | 5 mg | $225.00 | ||
Isoginkgetin is a splicing inhibitor that could reduce the processing of RNA targets for TFIIIC90, indirectly inhibiting its role in RNA Pol III transcription. | ||||||
Madrasin | 374913-63-0 | sc-507563 | 100 mg | $750.00 | ||
Madrasin is a splicing inhibitor that may reduce the pool of RNA transcripts that require TFIIIC90 for transcription. | ||||||